It has been claimed by the French drugmaker Sanofi that its lixisenatide, when used together with Lantus insulin, can prove helpful for Type 2 diabetes patients. The drug would be introduced in markets with the name Lyxumia.

Lyxumia has been characterized as the GLP-1 class of drugs which boost insulin in the body at the time when the level of glucose are extremely high. If the drug proves successful in treating diabetes, then Sanofi will become popular for treating diabetes.

Pierre Chancel, Senior Vice-president of Sanofi Diabetes said, “These positive results show that once-daily lixisenatide in combination with Lantus could be an innovative therapeutic option for the treatment of uncontrolled type 2 diabetes”.

The drug has already received green signal from the European authorities. However, Sanofi is at the present striking to get regulatory approval from the US. It is expected that the drug would become available in the US by the fourth quarter of next year.

A study was conducted to observe the outcomes of the usage of the drugs. It was found that those taking the Lyxumia had manageable side effects like vomiting and brief nausea. The drug has been accepted by the European Medicines Agency on 16th of November.

During trial of the drug, the patients with controlled glucose levels and higher after-meal HbA1c levels were prescribed with the drug. It was found that after giving them for 24 weeks HbA1c levels fell to an average of 6.96%.

While acknowledging the drug, Matthew Riddle, a Professor of Medicine and Head of the Diabetes Division, said that the drug is a new GLP-1 agonist with a mode of action which complements that of basal insulin. The drug is said to be potential of saving many lives from the consequences of Type 2 diabetes.